Company Announcement No statistically significant difference in progression free survival in ofatumumab plus chemotherapy treatment arm compared to rituximab plus chemotherapy Detailed data will be presented at an upcoming medical conference announced today that the Phase III study of ofatumumab ) plus chemotherapy versus rituximab plus ... (more)
http://ift.tt/Tn17Lv
http://ift.tt/Tn17Lv
No comments:
Post a Comment